Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 6/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ESRRA | P11474 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17723380 | 0.86 | CNR2 (0.50) | CNR2MCHR1CYP1A2CYP2C9HDAC3 | |
| SCHEMBL282980 | 0.86 | CNR2 (0.50) | CNR2MRGPRX4MCHR1ALDH1A1CYP2C19 | |
| SCHEMBL18963341 | 0.85 | CNR2 (0.49) | CNR2MRGPRX4MCHR1CYP1A2CYP2C9 | |
| SCHEMBL25336183 | 0.82 | CFTR (0.54) | CFTRMRGPRX4CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL4070406 | 0.81 | CFTR (0.62) | CFTRMRGPRX4ALDH1A1KDM4EHPGD | |
| SCHEMBL22175851 | 0.78 | KDM4E (0.51) | CFTRMRGPRX4CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL27781533 | 0.77 | KDM4E (0.60) | CFTRMRGPRX4CYP1A2CYP2C9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL22164233 | 0.77 | KDM4E (0.50) | CFTRMRGPRX4CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL475163 | 0.76 | CFTR (0.53) | CFTRMRGPRX4HDAC3HDAC6ALDH1A1 | |
| SCHEMBL284138 | 0.76 | CFTR (0.64) | CFTRMRGPRX4ALDH1A1CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2896615-A1 | Cannabinoid receptor ligands | AbbVie Bahamas Limited (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-8859596-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8188135-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2428507-A2 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2334646-A2 | SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010033543-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CFTR 1700/4885CNR2 2/4885MRGPRX4 28/4885 |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CFTR 1700/4885CNR2 2/4885MRGPRX4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.